当前位置: X-MOL 学术Nat. Nanotechnol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
COVID-19 vaccine development and a potential nanomaterial path forward.
Nature Nanotechnology ( IF 38.3 ) Pub Date : 2020-07-15 , DOI: 10.1038/s41565-020-0737-y
Matthew D Shin 1 , Sourabh Shukla 1 , Young Hun Chung 2 , Veronique Beiss 1 , Soo Khim Chan 1 , Oscar A Ortega-Rivera 1 , David M Wirth 1 , Angela Chen 1 , Markus Sack 3 , Jonathan K Pokorski 1, 4, 5 , Nicole F Steinmetz 1, 2, 4, 5, 6, 7
Affiliation  

The COVID-19 pandemic has infected millions of people with no clear signs of abatement owing to the high prevalence, long incubation period and lack of established treatments or vaccines. Vaccines are the most promising solution to mitigate new viral strains. The genome sequence and protein structure of the 2019-novel coronavirus (nCoV or SARS-CoV-2) were made available in record time, allowing the development of inactivated or attenuated viral vaccines along with subunit vaccines for prophylaxis and treatment. Nanotechnology benefits modern vaccine design since nanomaterials are ideal for antigen delivery, as adjuvants, and as mimics of viral structures. In fact, the first vaccine candidate launched into clinical trials is an mRNA vaccine delivered via lipid nanoparticles. To eradicate pandemics, present and future, a successful vaccine platform must enable rapid discovery, scalable manufacturing and global distribution. Here, we review current approaches to COVID-19 vaccine development and highlight the role of nanotechnology and advanced manufacturing.



中文翻译:

COVID-19疫苗的开发和潜在的纳米材料发展道路。

由于流行率高,潜伏期长和缺乏成熟的治疗方法或疫苗,COVID-19大流行已使数百万人感染,但没有明显减轻的迹象。疫苗是减轻新病毒株的最有前途的解决方案。可在创纪录的时间内获得2019年新型冠状病毒(nCoV或SARS-CoV-2)的基因组序列和蛋白质结构,从而可以开发灭活或减毒的病毒疫苗以及用于预防和治疗的亚单位疫苗。纳米技术使现代疫苗设计受益匪浅,因为纳米材料是抗原递送,佐剂和病毒结构模拟的理想选择。实际上,首个进入临床试验的候选疫苗是通过脂质纳米颗粒递送的mRNA疫苗。为了根除现在和将来的大流行,一个成功的疫苗平台必须能够快速发现,可扩展的制造和全球分销。在这里,我们回顾了COVID-19疫苗开发的当前方法,并重点介绍了纳米技术和先进制造技术的作用。

更新日期:2020-07-15
down
wechat
bug